Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
|
|
- Jessica Shelton
- 6 years ago
- Views:
Transcription
1 Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
2 2-year revision process WHO/HTM/TB/
3 Revision process Collaborative work of World Health Organization (WHO) staff at different levels, technical partners and national staff. May 2011: expert consultation in Geneva, Switzerland. June 2011: WHO s Strategic and Technical Advisory Group on TB (STAG-TB) July 2011: presentations and discussions with WHO regional and country staff, Geneva, and subsequent further consultation with WHO staff. October 2011: meeting of the DOTS Expansion Working Group, Lille, France. consultation with a wide range of countries and technical partners between November 2011 and March Seven countries (Belarus, Brazil, Cambodia, Djibouti, Estonia, Pakistan, Philippines) pilot the definitions and forms in 2012 and provide feedback 3
4 Objectives Outline the main changes in the 2013 document : 1) Definitions: basic TB & rifampicinresistant TB (RR-TB) 2) Reporting framework: basic TB & RR-TB 4
5 Definitions (1) 5 Basic TB (2009) M/XDR-TB (2008)
6 Definitions (2) Main motivation for revisions 1. Bacteriological confirmation needs to consider results from new WHO-approved rapid diagnostics (WRD), including Xpert MTB/RIF 2. Patients diagnosed with rifampicin-resistant TB (RR-TB) using WRD need separate enumeration from confirmed MDR-TB cases for surveillance and monitoring 3. Simplification of definitions of Cured and Treatment failed in RR- TB cohorts to allow their application while patient is still on treatment 4. Less judgmental language : defaulter replaced by Lost to follow-up and TB suspect by presumptive TB 6
7 Presumptive TB : a patient who presents with symptoms or signs suggestive of TB (previously TB suspect) TB case Definitions (3) A bacteriologically confirmed TB case : a biological specimen is positive by smear microscopy, culture or WRD. All such cases should be notified, regardless of whether TB treatment has started (previously Definite TB case; now includes explicit mention of WRD) A clinically diagnosed TB case : not bacteriologically confirmed but diagnosed with active TB by a clinician or other medical practitioner who has decided to give the patient a full course of TB treatment (previously a case of TB, not considered Definite) 7
8 Definitions (4) Classification by site of disease Pulmonary tuberculosis (PTB) : any TB case with involvement of the lung parenchyma or the tracheobronchial tree. Includes miliary and mixed PTB/extrapulmonary (specific mention of tracheobronchial tree) Extrapulmonary tuberculosis (EPTB) : any TB case with involvement of organs other than the lungs, e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges (no change) 8
9 Definitions (5) Classification by previous TB treatment history (1) New : never been treated for TB or have taken anti-tb drugs for less than 1 month (no change) Previously treated : have received 1 month or more of anti-tb drugs in the past (no change) 9
10 10 Definitions (6) Classification by previous TB treatment history (2) Main change is for the Previously treated cases in whom the focus is now on previous treatment history, independent of bacteriological confirmation or site of disease (NB: for RR-TB these groups are different). Relapse : previously treated for TB, were declared cured or treatment completed at the end of their most recent course of treatment, and are now diagnosed with a recurrent episode of TB (either a true relapse or a new episode of TB caused by reinfection) Treatment after failure : previously treated for TB and whose treatment failed at the end of their most recent course of treatment
11 Definitions (7) Classification by previous TB treatment history (3) Treatment after loss to follow-up : previously treated for TB and were lost to follow-up at the end of their most recent course of treatment (previously known as treatment after default) Other previously treated : previously treated for TB but whose outcome after their most recent course of treatment is unknown or undocumented (cases with unknown previous TB treatment history classified separately) Unknown previous TB treatment history : do not fit into any of the other categories (new group) 11
12 12 Classification by HIV status Definitions (8) HIV-positive TB patient refers to any TB case who has a positive result from HIV testing conducted at the time of TB diagnosis or other documented evidence of enrolment in HIV care 1, such as enrolment in the pre-art register or in the ART register once ART has been started. HIV-negative TB patient refers to any TB case who has a negative result from HIV testing conducted at the time of TB diagnosis. Any HIV-negative TB patient subsequently found to be HIV-positive should be reclassified accordingly. HIV status unknown TB patient refers to any TB case who has no result of HIV testing and no other documented evidence of enrolment in HIV care 1. If the patient s HIV status is subsequently determined, he or she should be reclassified accordingly. 1) A guide to monitoring and evaluation for collaborative TB/HIV activities (whqlibdoc.who.int/publications/2009/ _eng.pdf)
13 Definitions (9) Classification based on drug resistance (1) Main change : inclusion of rifampicin-resistant TB (RR-TB). RR-TB includes any resistance to rifampicin, whether monoresistance, multidrug resistance, polydrug resistance or extensive drug resistance. Category is not mutually exclusive with the others. Rifampicin resistance: resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-tb drugs. (new definition) 13
14 Definitions (10) Classification based on drug resistance (2) Monoresistance: resistance to one first-line anti-tb drug only (no change) Polydrug resistance: resistance to more than one first-line anti-tb drug (other than both isoniazid and rifampicin) (no change) Multidrug resistance: resistance to at least both isoniazid and rifampicin. (no change) Extensive drug resistance: resistance to any fluoroquinolone and to at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance. (no change) 14
15 Classification based on drug resistance (3) NOTE: Definitions (11) Monoresistance and polydrug resistance are usually applied to first-line drugs only (R, H, E and S). Future drug regimens may make it important to classify patients by their strain resistance patterns to fluoroquinolones, second-line injectable agents and any other drug for which reliable DST becomes available. 15
16 Treatment outcome definitions (1) Two sets of definitions for two, mutuallyexclusive treatment outcome cohorts : 1) Outcomes for TB patients, excluding patients treated for RR-TB ( Basic TB ) 2) Outcomes for RR-TB/MDR-TB/XDR-TB patients treated using second-line treatment ( RR-TB ) 16
17 Treatment outcome definitions (2) The first group ( Basic TB ) may include cases who have drug-susceptible TB, or other forms of resistance (eg, INH-resistance) not requiring a full secondline regimen for MDR-TB. Outcomes are assigned to all bacteriologically confirmed and clinically diagnosed TB cases including those who die or who are lost to follow-up before starting treatment. The second group ( RR-TB ) includes all RR-TB, MDR-TB and XDR-TB cases, confirmed or presumptive, started on combination second-line regimen for MDR-TB as per the local policy. Outcomes are assigned to all. For treatment outcome monitoring, only laboratory confirmed RR-TB (+ MDR-TB/XDR-TB ) are enumerated. A patient included under Basic TB who is later switched to a combination second-line regimen for MDR-TB, because of confirmed or presumptive RR- TB, is removed from the first group and included only in the RR-TB cohort. If no combination second-line regimen for MDR-TB is started the patient is retained in the first group and assigned an outcome accordingly. 17
18 Treatment outcome definitions (3) Basic TB: outcomes for TB patients, excluding patients treated for RR-TB (1) Two significant changes. 1) Treatment failed : a case confirmed to be MDR-TB is no longer automatically assigned this outcome. If the patient is started on a combination second-line regimen for MDR-TB the case is excluded from the Basic TB cohort when calculating treatment outcomes and transferred to the RR-TB cohort. If treatment with a combination second-line regimen for MDR-TB is not possible, the patient is kept in the Basic TB cohort and assigned an outcome from among those below. 2) Previous category Transfer out merged with Not evaluated 18
19 Treatment outcome definitions (4) Basic TB: outcomes for TB patients, excluding patients treated for RR-TB (2) Cured : a pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who was smear- or culture-negative in the last month of treatment and on at least one previous occasion (only pulmonary; initial bacteriological confirmation may be based on WRD) Treatment completed : a TB patient who completed treatment without evidence of failure BUT with no record to show that sputum smear or culture results in the last month of treatment and on at least one previous occasion were negative, either because tests were not done or because results are unavailable (no change) 19
20 Treatment outcome definitions (5) Basic TB: outcomes for TB patients, excluding patients treated for RR-TB (3) Treatment failed : sputum smear or culture is positive at month 5 or later during treatment (no longer includes systematically any case with confirmed MDR-TB) Died : for any reason before starting or during the course of treatment (no change) Lost to follow-up : did not start treatment or treatment interrupted for 2 consecutive months or more (previously Default) Not evaluated : no treatment outcome is assigned. Includes cases transferred out to another treatment unit as well as cases for whom the treatment outcome is unknown to the reporting unit (now also includes previous Transfer out category) Treatment success : cured + treatment completed (no change) 20
21 Treatment outcome definitions (6) RR-TB: outcomes for RR-TB/MDR-TB/XDR-TB patients treated using second-line treatment (1) Cured : Treatment completed as recommended by the national policy without evidence of failure AND three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase (negative cultures counted after the intensive phase no longer limited to last 12 months of treatment) Treatment completed : Treatment completed as recommended by the national policy without evidence of failure BUT no record that three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase (changes only insofar as applied to Cured) 21
22 Treatment outcome definitions (7) RR-TB: outcomes for RR-TB/MDR-TB/XDR-TB patients treated using second-line treatment (2) Treatment failed : Treatment terminated or need for permanent regimen change of at least two anti-tb drugs because of: - lack of conversion by the end of the intensive phase, or - bacteriological reversion in the continuation phase after conversion to negative, or - evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs, or - adverse drug reactions (ADRs) (definition now determined primarily by changes required to the regimen as a result of non response as determined by lack of conversion, reversion, amplification or ADRs) 22
23 Treatment outcome definitions (8) RR-TB: outcomes for RR-TB/MDR-TB/XDR-TB patients treated using second-line treatment (3) Lack of conversion by the end of the maximum intensive phase used by the programme. If no maximum duration is defined, an 8-month cut-off is proposed. If regimens do not have a clear distinction between intensive and continuation phases, a cut-off 8 months after the start of treatment is suggested to determine when the criteria for Cured, Treatment completed and Treatment failed start to apply. Reversion (to positive): after an initial conversion, 2 consecutive cultures, at least 30 days apart, are positive. For Treatment failed, reversion considered only when it occurs in the continuation phase. 23
24 Treatment outcome definitions (9) RR-TB: outcomes for RR-TB/MDR-TB/XDR-TB patients treated using second-line treatment (4) Died : for any reason during the course of treatment (no change) Lost to follow-up : treatment interrupted for 2 consecutive months or more (previously Defaulted) Not evaluated : no treatment outcome is assigned (This includes cases transferred out to another treatment unit and whose treatment outcome is unknown) (now also includes previous Transferred out category) Treatment success: cured and treatment completed (no change) 24
25 Reporting framework (1) M/XDR-TB (2008)
26 Reporting framework (2) Main motivation for revisions 1. Combining outcome reporting for drug-sensitive and RR-TB for countries where programmatic management of DR-TB is incorporated ( mainstreamed ) in the NTP 2. Childhood TB reporting was incomplete because age disaggregation was previously limited to sputum smear-positive TB, which is uncommon in children 3. There was a delay of two calendar years in the reporting of cotrimoxazole preventive therapy (CPT) and antiretroviral therapy (ART) in TB/HIV because these data were collected only in the treatment outcome reports and not in the case registration reports 26
27 Reporting framework (3) 8 revised forms, registers and reports Forms for human resource or management of consumables not covered in this document Revised forms and reports for RR-TB will be discussed in greater detail in the forthcoming Companion handbook to the 2011 WHO guidelines for the programmatic management of drug-resistant tuberculosis 27
28 Reporting framework (4) Request for examination of biological specimen for TB (1) Main changes : not focused solely on sputum; inclusion of LPA & Xpert MTB/RIF test results; HIV-status HIV status and previous treatment status included to assess adherence to, and results of, testing algorithms. HIV status may have to be omitted to comply with national confidentiality regulations If several types of specimen (e.g. sputum and other fluids) are to be analysed, separate request forms to accompany each specimen If multiple analyses (e.g. culture and DST on the same sputum sample) are requested, results should be sent from the laboratory to the requestor as they become available. It may therefore be practical to produce the request forms in booklets with self-carbonated paper. Some countries may want to use separate forms to request smear, culture, Xpert MTB/RIF or DST separately. 28
29 Reporting framework (5) Request for examination of biological specimen for TB (2) Xpert MTB/RIF results reporting codes T = MTB detected, rifampicin resistance not detected RR = MTB detected, rifampicin resistance detected TI = MTB detected, rifampicin resistance indeterminate N = MTB not detected I = invalid / no result / error 29
30 Reporting framework (6) Basic management unit (BMU) TB register (1) This register (sometimes called the district TB register) is used for recording the data needed to monitor BMU performance. It is intended primarily to generate indicators and reports about TB patients. It is also commonly used to summarize testing results and treatment decisions in order to determine whether basic diagnostic and treatment guidelines are correctly implemented. The register should contain the records of all patients diagnosed with TB and eligible for TB treatment, including those diagnosed with RR-TB or MDR-TB, regardless of whether treatment was actually started. All of these cases are notifiable and should be included in the summary case notification reports sent to higher levels. The registration date is the date on which the BMU decides that a patient has TB and is eligible for treatment. 30
31 Reporting framework (7) Basic management unit (BMU) TB register (2) Bacteriological examination before the start of treatment ( month 0 ) now allows for results from Xpert MTB/RIF test. Space is provided for recording whether the case is RR-TB or MDR-TB, replacing X-ray result Treatment categories have now changed: - initial regimen with first line drugs (previously Category 1 or 3) - retreatment regimen with first line drugs (previously Category 2) - second-line treatment regimen (previously Category 4) Unknown previous TB treatment history new Revised treatment outcome definitions Dates for HIV testing and start of ART/CPT removed from register 31
32 Reporting framework (8) 32
33 Reporting framework (9) Second-line TB treatment register (1) This register is intended primarily to keep a record of those data needed for generating indicators and reports of patients on combination second-line regimens for MDR-TB (including RR-TB). This register is also commonly used to follow, at a glance, the adequacy of testing and treatment decisions. In contrast to the BMU register, it is restricted to patients who have actually started on a second-line TB treatment regimen. 33
34 Reporting framework (10) Second-line TB treatment register (2) Replaces Category IV Register RR-TB or MDR-TB cases registered, confirmed or presumptive Bacteriological examination before the start of treatment ( month 0 ) now allows for results from Xpert MTB/RIF test. Unknown previous TB treatment history new Revised treatment outcome definitions Dates for HIV testing and start of ART/CPT removed from register 34
35 Reporting framework (11) Laboratory register for smear microscopy and Xpert MTB/RIF For laboratories undertaking both sputum-smear microscopy and Xpert MTB/RIF examinations. When serial sputa are tested using microscopy, results are recorded on the same line. This also applies if both direct sputum smear microscopy and Xpert MTB/RIF examinations are carried out for the same patient. HIV status and previous treatment status are included so that adherence to, and effectiveness of, testing algorithms can be assessed. HIV status can be omitted if necessary to comply with national confidentiality laws. Programmes could have separate registers for smear and Xpert MTB/RIF examinations rather than a combined register if these tests are performed in different locations. In such cases common fields should appear in both registers, and fields specific to each test should appear only in the relevant register. 35
36 Reporting framework (12) Laboratory register for culture, Xpert MTB/RIF and drug susceptibility testing (1) For laboratories capable of undertaking more advanced specimen testing (culture, Xpert MTB/RIF, DST), such as reference labs. The diagnostic method (culture or Xpert MTB/RIF) is indicated in the first two columns under Type of examination. HIV status and previous treatment status are included so that adherence to, and effectiveness of, testing algorithms can be assessed. HIV status can be omitted if necessary to comply with national confidentiality laws. 36
37 Reporting framework (13) 37
38 Reporting framework (14) Laboratory register for culture, Xpert MTB/RIF and drug susceptibility testing (2) Programmes could have registers with any combination of culture, Xpert MTB/RIF or DST rather than a combined register with all tests, depending on circumstances. In such cases common fields should appear in both registers, and fields specific to each test should appear only in the relevant register. Laboratories using different methods for DST may include a separate column to indicate details of the test (solid media DST; liquid media DST; direct LPA; indirect LPA) if they wish to compile reports based on test type. 38
39 Reporting framework (15) Quarterly report on TB case registration in the BMU (1) The standard aggregated report of cases as in the BMU TB register and of laboratory activity as in the laboratory register Cases are now stratified by three different categories of site of disease + bacteriological confirmation / clinical diagnosis combinations, as well as four previous TB history categories Incident cases (new and relapses) are broken down by age group and sex 39
40 Reporting framework (16) Quarterly report on TB case registration in the BMU (2) Yield of all bacteriological confirmatory testing of patients with presumptive TB Number of HIV-positive patients on ART and CPT during the quarter. This is a change from the 2006 version of the forms and reports where ART and CPT coverage was compiled only in the treatment outcome report, meaning that assessment of ART and CPT coverage became available nationally a minimum of 12 months after registration 40
41 Reporting framework (17) Quarterly report on TB treatment outcomes in the BMU The standard quarterly report for all TB cases that have not been started on combination second-line regimens for MDR-TB (or RR- TB) 4 outcome cohorts for (i) new & relapse by bacteriological confirmation, (ii) other retreatment and (iii) TB/HIV cases + Coverage of ART and CPT among HIV-positive TB patients 41
42 Reporting framework (18) Combined annual treatment outcomes report for basic TB and for RR-TB/MDR-TB This new form captures on one sheet the outcomes for annual cohorts of patients on first-line and second-line TB treatment. It is targets decentralized MDR-TB services where both types of treatment are available Block 1 is the standard basic TB treatment cohort annual report for the year minus 2 (e.g. the 2011 cohort is assessed in 2013), with four separate cohorts (as per quarterly report) Block 2 is for the second-line treatment outcome cohort of the year before that of Block 1 (i.e. year minus 3; e.g. the 2010 RR-TB cohort is assessed in 2013) (Now includes all types of RR-TB combined) 42
43 Reporting framework (19) Combined annual treatment outcomes report for basic TB and for RR-TB/MDR-TB 43
44 Move towards automated solutions WHO/HTM/TB/ whqlibdoc.who.int/publications/2012/ _eng.pdf
45 Additional slides : Indicators 45
46 46
47 47
48 48
49 Compendium of Indicators for M&E of NTPs 49 WHO/HTM/TB/
50 Indicators for RR-TB / MDR-TB / XDR-TB (1) Released just before WHO s endorsement of Xpert MTB/RIF Focused on MDR-TB and XDR-TB
51 Indicators for RR-TB / MDR-TB / XDR-TB (2) - Objective: minimum indicators for national or project level monitoring and - suitable for different partners (WHO, TGF) - easily extracted manually or electronically - conform to what was used in past and DOTS system - Focus on indicators rather than forms 51
52 Indicators for RR-TB / MDR-TB / XDR-TB (3) Indicators being updated in the «Companion handbook to the 2011 WHO guidelines for PMDT», due out in 2013 Dedicated Chapter & Annexes 52
53 Indicators for RR-TB / MDR-TB / XDR-TB (4) Indicator Group Cohort Computed Stratification Detection (4) 6 months 3 months after end of semester Risk categories Enrolment (4) 6 months 1 month after end of semester Children, females, HIV-positive on ARV Interim results (5) 3 months 9 months after end of quarter None Final outcomes (6) 12 months 24 months after end of year HIV positive (success and death); XDR * * Recommended stratification as per conditions specified in instructions 53
54 Indicators for RR-TB / MDR-TB / XDR-TB (5) Overall timeline Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Detection, Enrolment : Interim results : Final outcomes : 2 yearly 4 yearly 1 yearly 54
55 Indicators for RR-TB / MDR-TB / XDR-TB (6) Detection Risk category (list as many as exist) Risk category 1 (specify) Risk category 2 (specify) Total Total Number of TB cases With results for H & R Resistant to both H & R (MDR) With MDR and tested for FQN & 2 nd line inj. No. of MDR-TB cases with information on interval Interval between suspicion and DST results (days) Mean Minimum Maximum 55
56 Indicators for RR-TB / MDR-TB / XDR-TB (7) Enrolment TB patient type All patients eligible for treatment* < 15 y Female Identified during assessment period Enrolled on M(X)DR-TB treatment during period of assessment Confirmed MDR Confirmed MDR, HIV+ on ART Confirmed MDR, HIV+ not on ART Confirmed XDR Number of MDR-TB cases with information on interval Interval between DST results and start of treatment (in days) Mean Minimum Maximum * suspected or confirmed MDR 56
57 Indicators for RR-TB / MDR-TB / XDR-TB (8) Interim results Number of patients started on MDR-TB treatment found not to have MDR Number of patients started on treatment for XDR-TB found not to have XDR 57
58 Indicators for RR-TB / MDR-TB / XDR-TB (9) Final outcomes TB patient type No of cases started on treatment Cured Treatment completed Treatment failed Died Lost to follow-up Not evaluated N N N N N N All confirmed RR-TB/MDR-TB cases HIV+ve RR- TB/MDR-TB cases* All confirmed XDR-TB cases * * Recommended stratification only when conditions are frequent (see main document) 58
Assessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM
ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to
More informationIndicators for MDR-TB detection and outcomes
Indicators for MDR-TB detection and outcomes Dennis FALZON TB surveillance and surveys: A training workshop for consultants Geneva, Switzerland - 26 May 2011 Reference 2 Aggregated forms pages 161 162
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationMultidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationANALYSIS AND USE OF HEALTH FACILITY DATA. Guidance for tuberculosis programme managers
ANALYSIS AND USE OF HEALTH FACILITY DATA Guidance for tuberculosis programme managers WORKING DOCUMENT SEPTEMBER 2018 World Health Organization 2018 All rights reserved. This is a working document and
More informationMinistry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)
Ministry of Health National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015) Contents Executive summary... 2 Background... 3 National Tuberculosis Program Overview... 3
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationUGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
MINISTRY OF HEALTH UGANDA TIOL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME Revised Strategic Plan 2015/16-2019/20 Monitoring and Evaluation Plan Narrative of the Operational, Budget and Technical Assistance
More informationOnline Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
More informationEnd TB Strategy top 10 indicators: current status in participant countries
End TB Strategy top 10 indicators: current status in participant countries Dennis FALZON Global TB Programme, WHO/HQ Geneva Regional WHO / Global Fund meeting Kenya 20 September 2016 Objectives of the
More informationOnline Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
More informationInformation Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis
Information Note WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis In order to ensure that the upcoming comprehensive revision of WHO policies on treatment
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms March 2017 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient access
More informationThe Evaluation of Effectiveness and Safety of Novel Shorter. Treatment Regimens for Multidrug-Resistant Tuberculosis
The Evaluation of Effectiveness and Safety of Novel Shorter Treatment Regimens for Multidrug-Resistant Tuberculosis Operational Research Protocol Template May 2018 A publication of the Global Drug-resistant
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms Revised June 2018 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient
More informationXpert MTB/RIF test Rollout and Implementation Plan
Xpert MTB/RIF test Rollout and Implementation Plan UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME 6 Samora Machel Avenue P.O. Box 9083 11478
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationResearch Article Characteristics and Treatment Outcomes of Retreatment Tuberculosis Patients in Benin
Tuberculosis Research and Treatment Volume 2016, Article ID 1468631, 7 pages http://dx.doi.org/10.1155/2016/1468631 Research Article Characteristics and Treatment Outcomes of Retreatment Tuberculosis Patients
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationAnnex 1. Methods for evidence reviews and modelling
WHO/HTM/TB/2011.6a. Methods for evidence reviews and modelling Questions for the 2011 update of the Guidelines for the programmatic management of drug-resistant tuberculosis (for Outcomes please see Table
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationInternational Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationXpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationControlling TB in the era of HIV
Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationAnnex 2. GRADE glossary and summary of evidence tables
WHO/HTM/TB/2011.6b. GRADE glossary and summary of evidence tables GRADE glossary Absolute effect The absolute measure of intervention effects is the difference between the baseline risk of an outcome (for
More information11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 1 OUTLINE OF PRESENTATION Introduction Burden Of The Disease Evolution Of RNTCP Goals And Objectives Of RNTCP DOTS Stop TB Strategy Organization RNTCP Endorsed
More informationCosting of the Sierra Leone National Strategic Plan for TB
Costing of the Sierra Leone National Strategic Plan for TB 2016-2020 Introduction The Government of Sierra Leone established the National Leprosy Control Programme in 1973 with support from the German
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More information4-6 Km-Mfx-Pto-Cfz-Z-H high-dose -E / 5 Mfx-Cfz-Z-E
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions Version: 20 December 2016 These FAQs are to be read
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationSoedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital There were an estimated 10.4 million new TB cases in 2015, higher than
More informationSession-1: Template for country presentation (EXISTING Indicators)
Session-1: Template for country presentation (EXISTING Indicators) Instruction This presentation is expected to provide Country perspective on use of following Existing indicators among the top 10 indicators
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationTB Situation in Zambia/ TB Infection Control Program. Dr N Kapata Zambia National TB/Leprosy Control Programme Manager
/ TB Infection Control Program Dr N Kapata Zambia National TB/Leprosy Control Programme Manager Background Major public health problem Current (2014) notification rate is at 286/ 100,000 population. The
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More information2006 Report. Tuberculosis Control. in the Western Pacific Region
IFC Report Tuberculosis Control in the Western Pacific Region Prepared by The Stop TB Unit in the WHO Regional Office for the Western Pacific Region, Dongil Ahn, Philippe Glaziou, Yao Hongyan, Pieter van
More informationXpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work
Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection Results of Group Work DOTS expansion and enhancement Objective This group deals with the majority
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationWR s Speech on inaugural ceremony of Community based Programmatic Management of Drug resistance TB (CPMDT).
WR s Speech on inaugural ceremony of Community based Programmatic Management of Drug resistance TB (CPMDT). The Chief guest Prof. Dr. A.F.M. Ruhul Haque M.P Hon ble Minister, Ministry of Health and Family
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationPlanning for the implementation of new diagnostic tests
Planning for the implementation of new diagnostic tests Dr Christopher Gilpin Laboratories, Diagnostics & Drug Resistance WHO Global TB Programme, Geneva GLOBAL TB PROGRAMME Workshop on the development
More informationIPT IMPLEMENTATION- SWAZILAND EXPERIENCE
IPT IMPLEMENTATION- SWAZILAND EXPERIENCE Gugu Mchunu-National TB/HIV coordinator Programmatic Management of Latent TB infection consultation meeting Seoul, Republic of Korea,27-28 APRIL,2016 TB Epidemiology
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationSoedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital MDR-TB is a public health crisis 480 000 people developed MDR-TB in
More informationEstimates of TB incidence, prevalence and mortality. Philippe Glaziou Cairo, October 2009
Estimates of TB incidence, prevalence and mortality Philippe Glaziou Cairo, October 2009 Outline Main sources of information Incidence From incidence to prevalence From incidence to mortality TB/HIV MDR-TB
More informationTuberculosis in England 2018 report (presenting data to end of 2017) Tables and figures slide set
Tuberculosis in England 2018 report (presenting data to end of 2017) Tables and figures slide set Number of TB notifications and rates, England, 1971-2017 2 Tuberculosis in England: 2018 report, Office
More informationPrevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011
Original Research Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Hoa Binh Nguyen, ab Nhung Viet Nguyen, ac Huong Thi Giang Tran,
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationPCS GUIDELINES. Diagnosis & Management of Drug-susceptible Tuberculosis. A National Clinical Guideline
PCS GUIDELINES Diagnosis & Management of Drug-susceptible Tuberculosis A National Clinical Guideline 2017 Table of content Content Foreword Message by the President, Pakistan Chest Society Introduction
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationEpidemiology of tuberculosis in Europe. Marieke J. van der Werf European Centre for Disease Prevention and Control Amsterdam, 22 September 2014
Epidemiology of tuberculosis in Europe Marieke J. van der Werf European Centre for Disease Prevention and Control Amsterdam, 22 September 2014 Tuberculosis surveillance in the EU Aim: To provide a complete
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationIPT BOTSWANA EXPERIENCE
IPT BOTSWANA EXPERIENCE Oaitse I Motsamai RN, MW, B Ed, MPH Ministry of Health Botswana 11 th November 2008 Addis Ababa, Ethiopia OUTLINE Botswana context Rationale for IPT in Botswana Pilot Current Programme
More informationMDR TB. Jaime C. Montoya MD, MSc
MDR TB Jaime C. Montoya MD, MSc Definitions of MDRTB and XDRTB Historical background of the problem Global and Philippine Data on MDRTB Risk Factors Diagnosis Treatment Research Gaps Guidelines for the
More informationApplication of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes
Application of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes Dr Amal Bassili Stop TB unit, WHO, Regional Office for the Eastern Mediterranean Surveillance
More informationDr Richard Christopher,(Pediatrician) Ministry of Health and Social Welfare NTLP- TANZANIA Tanzania. Childhood TB Roadmap Paris 0ctober 29
Dr Richard Christopher,(Pediatrician) Ministry of Health and Social Welfare NTLP- TANZANIA Tanzania Childhood TB Roadmap Paris 0ctober 29 Status of childhood TB in Tanzania Child TB linkages with National
More informationMultidrug-resistant Tuberculosis - World, Europe, Switzerland
Multidrug-resistant Tuberculosis - World, Europe, Switzerland Magglingen March 23, 2017 peter.helbling@bag.admin.ch Topics Definitions Epidemiology of TB and MDR-TB worldwide Treatment outcome results
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationTB/HIV in the WHO European Region Overview, Priorities & Response
TB/HIV in the WHO European Region Overview, Priorities & Response 16 th Core Group Meeting TB/HIV Working Group Stop TB Partnership Almaty, Kazakhstan May 2010 Martin Donoghoe Andrei Dadu, Smiljka de Lussigny
More informationRamesh P. M.*, Saravanan M.
International Journal of Advances in Medicine Ramesh PM et al. Int J Adv Med. 2018 Jun;5(3):561-565 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181663
More informationAnnex A: Impact, Outcome and Coverage Indicators (including Glossary of Terms)
IMPACT INDICATORS (INDICATORS PER GOAL) HIV/AIDS TUBERCULOSIS MALARIA Reduced HIV prevalence among sexually active population Reduced HIV prevalence in specific groups (sex workers, clients of sex workers,
More informationEffectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR
More informationWHO treatment guidelines for isoniazid-resistant tuberculosis
Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World
More informationNATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis
NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:
More information2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges
Outline of what it will take Tuberculosis Elimination 25: Global and Local Challenges Anne Fanning, MD November 9, 211 21 global TB trends, goals How DOTS happens at country level - an exercise New strategies
More informationTuberculosis in Wales Annual Report 2015
Tuberculosis in Wales Annual Report 2015 Author: Communicable Disease Surveillance Centre Date: 10/03/2016 Version: 1 Status: Final Intended Audience: Health Purpose and Summary of Document: This annual
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationTUBERCULOSIS IN JAPAN
TUBERCULOSIS IN JAPAN ANNUAL REPORT 2017 Tuberculosis Surveillance Center-RIT/JATA J a p a n 0 About the Tuberculosis Surveillance Center The Tuberculosis Surveillance Center, located within the Department
More informationXpert MTB/RIF. implementation manual. Technical and operational how-to : practical considerations IMPLEMENTATION MANUAL TUBERCULOSIS PERFORMANCE
Xpert MTB/RIF implementation manual Technical and operational how-to : practical considerations TB NEW DIAGNOSTIC TESTS IMPLEMENTATION MANUAL DRUG-RESISTANCE TB/HIV RAPID TB TEST TUBERCULOSIS ACCURACY
More informationStrengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation
LOGO Strengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation Irina A.Vasilyeva Chief TB Specialist of the Russian Ministry of Health Central TB Research Institute,
More information: uptake and impact of Xpert MTB/RIF
Photo: Riccardo Venturi 21-215: uptake and impact of Xpert MTB/RIF Wayne van Gemert WHO Global TB Programme, Geneva Joint Partners Forum for Strengthening and Aligning TB Diagnosis and Treatment 27-3 April
More informationManagement of MDR TB in special situations. Dr Sarabjit Chadha The Union
Management of MDR TB in special situations Dr Sarabjit Chadha The Union MDR TB in special situations Pregnancy Breastfeeding Contraception Renal Insufficiency Diabetes Pregnancy and TB Pregnancy is not
More informationINTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationAuthor s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha
More informationChildhood TB: experience of Kazakhstan, national policy and issues of the outpatient treatment
Childhood TB: experience of Kazakhstan, national policy and issues of the outpatient treatment K.S. Serikbayeva National coordinator of childhood TB management Wolfheze, 2013 Republic of Kazakhstan Total
More informationSame-day diagnosis of tuberculosis by microscopy. Policy statement
Same-day diagnosis of tuberculosis by microscopy Policy statement March 2010 Contents Abbreviations Executive summary 1. Background 2. Evidence for policy formulation 2.1 Synthesis of evidence 2.2 Management
More informationCurrent status of implementation and monitoring and evaluation of collaborative TB/HIV activities. Avinash Kanchar
Current status of implementation and monitoring and evaluation of collaborative TB/HIV activities Avinash Kanchar Outline WHO guide to M&E of collaborative TB/HIV activities: 2015 Reporting status on Global
More informationEXPERT GROUP MEETING REPORT
Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children DRUG-RESISTANCE TB/HIV RAPID TB TEST TUBERCULOSIS ACCURACY RECOMMENDATIONS
More informationRole of RNTCP in the management MDR-TB
Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A
More informationTB in the SEA Region. Review Plans and Progress. Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO
TB in the SEA Region Review Plans and Progress Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO The SEA Region: 25% of the world s people, but >33% of TB patients Eastern M editerranean Region 5%
More informationModern TB Diagnostic Services: Optimizing the Old with the New
Modern TB Diagnostic Services: Optimizing the Old with the New 6 th Global Laboratory Initiative (GLI) Partners Meeting incorporating Global consultation of the TB SRL Network Global Forum of Xpert MTB/RIF
More informationOverview of the Presentation
Overview of the Presentation Definitions(TBCase, MDR-TB & XDR-TB) Global Tuberculosis (TB,HIV/TB,MDR & XDR)Scenario & Trend Risk factor for TB Natural history of TB Types of TB & Trends of Extra Pulmonary
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More information